Why this matters
Until now, every semaglutide obesity option was an injection, or a diabetes-only pill (Rybelsus). The Wegovy pill delivers injection-level weight loss in tablet form for the first time. Novo Nordisk positioned it as broadly accessible, launching through 70,000+ pharmacies including CVS and Costco, plus telehealth partners such as Ro, LifeMD, and WeightWatchers. For people who avoid needles, that is a meaningful new door into treatment.
How it performed
Pill vs injection
| Feature | Oral Wegovy (pill) | Injectable Wegovy |
|---|---|---|
| Form | Once-daily tablet | Once-weekly injection |
| Dose | 25 mg | 2.4 mg |
| Taking it | Empty stomach, plain water, then wait | Any time, with or without food |
| Avg weight loss | ~14-17% | ~15% |
| Cardiovascular | MACE risk reduction | MACE risk reduction |
How the pill is taken
The oral tablet must be swallowed on an empty stomach with a small sip of plain water, followed by a wait before eating, drinking, or taking other medicines. That routine is stricter than a weekly injection, so adherence habits matter. As with all semaglutide, the dose is titrated up gradually to limit gastrointestinal side effects, which in OASIS 4 mirrored those seen with the injection: nausea, diarrhea, and vomiting, mostly mild to moderate.
Access and cost
Novo Nordisk framed the launch around affordability, with a starting-dose self-pay offer near $149 per month (about $5 per day) and wide pharmacy distribution. Actual cost still depends on insurance, dose, and pharmacy. The pill’s arrival reshapes the comparison landscape: patients now weigh oral semaglutide against injectable semaglutide, injectable tirzepatide, and the oral orforglipron pill, each with different efficacy, routine, and price. See our semaglutide vs tirzepatide guide.
What it means for compounded semaglutide
The approval does not change the status of compounded semaglutide, which remains not FDA-approved and legally available only through narrow patient-specific pathways since the shortage resolved. But an affordable, FDA-approved pill weakens the historic argument that compounded routes are the only accessible option, and it gives clinicians a verified alternative to offer. Anyone currently on compounded semaglutide may reasonably revisit the decision with a clinician now that an approved oral option exists.
Bottom line
The Wegovy pill is a genuine milestone: injection-level results without a needle, FDA-approved, with cardiovascular benefit and comparatively accessible pricing. It is not automatically the best choice for everyone — injectable tirzepatide still leads on average weight loss, and the daily empty-stomach routine suits some people better than others — but it meaningfully widens the menu of approved treatments.
Frequently asked questions
Is there a semaglutide pill for weight loss now?
Yes. The FDA approved the Wegovy pill (oral semaglutide 25 mg) on December 22, 2025, the first oral GLP-1 for chronic weight management; it launched in early January 2026.
How much weight did people lose on the pill?
In OASIS 4, oral semaglutide 25 mg produced about 16.6% average weight loss at 64 weeks when taken as directed (roughly 14% across all participants), versus 2.7% on placebo.
How is the Wegovy pill taken?
Once daily on an empty stomach with a small sip of plain water, followed by a waiting period before eating, drinking, or other medicines.
What does it cost?
Novo Nordisk advertised a starting-dose self-pay offer near $149 per month; actual cost depends on insurance, dose, and pharmacy.
References
- Novo Nordisk. FDA approves Wegovy pill (oral semaglutide 25 mg). December 22, 2025.
- AJMC. FDA approves oral semaglutide as first GLP-1 pill for weight loss. 2026.
- Novo Nordisk. Wegovy pill now broadly available across America. January 5, 2026.
- New England Journal of Medicine. OASIS 4 topline results. 2025.